Caas Capital Management LP Sarepta Therapeutics, Inc. Transaction History

Caas Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $19,667 - $25,765	195 Added 0.44%	44,929 $5.82 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $2.22 Million - $3.5 Million	-29,326 Reduced 39.6%	44,734 $4.95 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $517,819 - $730,514	8,260 Added 12.55%	74,060 $5.55 Million
Q1 2022 May 13, 2022	SELL	$63.15 - $90.42 $1.43 Million - $2.05 Million	-22,630 Reduced 25.59%	65,800 $5.14 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $462,598 - $595,128	5,986 Added 7.26%	88,430 $7.96 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $310,059 - $434,656	4,700 Added 6.05%	82,444 $7.62 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $1.68 Million - $2.11 Million	24,266 Added 45.38%	77,744 $6.04 Million
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $3.86 Million - $9.04 Million	53,478 New	53,478 $3.99 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.